Dietary intake of n-3 long-chain polyunsaturated fatty acids and risk of myocardial infarction in coronary artery disease patients with or without diabetes mellitus: a prospective cohort study

Table 2 Serum fatty acid profile in percentage by weight (wt%) measured in 723 participants

	Non-diabetes HbA1c <5.7% n = 380	Pre-diabetes HbA1c ≥5.7% n = 259	Diabetes^a n = 84	P ^b
Total FAs (mg/L)	3,790 (3,680 to 3,900)^c	3,680 (3,560 to 3,810)	4,050 (3,820 to 4,300)	0.02
Saturated FAs	33.2 (32.9 to 33.4)	33.2 (32.9 to 33.5)	34.0 (33.5 to 34.5)	0.01
Monounsaturated FAs	22.9 (22.5 to 23.2)	23.2 (22.7 to 23.6)	24.0 (23.2 to 24.8)	0.03
n-6 PUFAs	35.0 (34.4 to 35.5)	34.5 (33.9 to 35.2)	32.8 (31.8 to 33.9)	0.002
n-3 PUFAs	7.2 (7.0 to 7.5)	7.4 (7.1 to 7.8)	7.2 (6.6 to 7.8)	0.61
α-Linolenic acid	0.71 (0.69 to 0.73)	0.73 (0.70 to 0.75)	0.72 (0.68 to 0.77)	0.38
Eicosapentaenoic acid	1.80 (1.68 to 1.92)	1.91 (1.76 to 2.07)	1.78 (1.54 to 2.05)	0.49
Docosapentaenoic acid (n-3)	0.62 (0.60 to 0.63)	0.63 (0.61 to 0.65)	0.62 (0.58 to 0.65)	0.55
Docosahexaenoic acid	3.69 (3.56 to 3.82)	3.73 (3.58 to 3.90)	3.63 (3.37 to 3.91)	0.79
n-3 PUFA / n-6 PUFA ratio	0.21 (0.20 to 0.22)	0.22 (0.20 to 0.23)	0.22 (0.20 to 0.24)	0.41

^aDiabetes was defined as clinically diagnosed, or as having a fasting glucose ≥7.0 or a non-fasting glucose ≥11.1 mmol/L. ^bCalculated by using one-way analysis of covariance, after log transformation, adjusted for age, sex, and statin dose. ^cEstimated marginal means; 95% CI in parentheses (all such values). FAs, fatty acids; HbA1c, glycosylated hemoglobin; PUFAs, polyunsaturated fatty acids.

ISSN: 1741-7015